Pfizer cuts full-year outlook due to declining sales of Covid-19-related products

[admin]

Shares of Pfizer are in retreat on the first day of trading after the drug company said sales of its COVID-19 vaccine and its coronavirus treatment are in less than expected and cut revenue expectations for the year by $9 billion. Falling sales of both clipped sales in the second quarter, but Pfizer said in August that it expected a rebound in the second half of 2023. Shares of Pfizer slid nearly 3% before the opening bell Monday and Moderna, which makes a competing vaccine, slid as well. The co